Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.


DOD - 9482 - Department of Defense Pharmacy and Therapeutics Committee - Statutory (Congress Created)
Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameDepartment of Defense Pharmacy and Therapeutics CommitteeAgency NameDepartment of Defense
Fiscal Year2004Committee Number9482
Original Establishment Date Committee StatusTerminated
Actual Termination Date9/30/2004Committee URL 
New Committee This FYNoPresidential Appointments*No
Terminated This FYYesMax Number of Members*28
Current Charter Date5/30/2002Designated Fed Officer Position Title*Director, DoD Pharmacy Programs
Date Of Renewal Charter Designated Federal Officer PrefixCOL
Projected Termination Date Designated Federal Officer First Name*James
Exempt From Renewal*NoDesignated Federal Officer Middle NameH
Specific Termination AuthorityDesignated Federal Officer Last Name*Young
Establishment Authority*Statutory (Congress Created)Designated Federal Officer Suffix
Specific Establishment Authority*Designated Federal Officer Phone*703-681-0064
Effective Date Of Authority* Designated Federal Officer Fax*
Exempt From EO 13875 Discretionary Cmte Designated Federal Officer Email*james.young@tma.osd.mil
Committee Type*Continuing
Presidential*No
Committee Function*Other Committee
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Terminate
Legislation to Terminate Required 
Legislation Status 
How does cmte accomplish its purpose?*Created by the National Defense Authorization Act, this committee is tasked with developing a uniform formulary of pharmaceutical agents, review such formulary on a periodic basis, and make additional recommendations as necessary . The committee is responsible for encouraging the use of safe, effective pharmaceutical agents that will produce the desired outcomes of drug therapy at a reasonable cost to DoD. The committee will 1) consider the relative safety, effectivemess, cost, and other pertinent factors in deciding which pharmaceutical agents are included on the uniform formulary and tne Basic Core Formulary ( BCF - applies only to Military Treatment Facilities); 2) conduct therapeutic drug class reviews on a scheduled basis; 3) evaluate requests for changes to the uniform formulary and the BCF within the Military Health System.
How is membership balanced?*All 22 voting members and additional non-voting members will have expertise in identifying the medical and pharmaceutical needs of the population served throughout the Military Health System. There will be representatives from all the services, physicians, pharmacists, TRICARE providers, contracting experts
How frequent & relevant are cmte mtgs?*This committee is expected to meet four times per year, once underway.
Why advice can't be obtained elsewhere?*Required by Public Law 106-65, section 701 (amends 10USC Chapter 55 by inserting a new section 1074g, entitled Pharmacy Benefits Program.)
Why close or partially close meetings?Meetings will need to be closed due to discussion of proprietary information and procurement sensitive costing information.
Recommendation RemarksThe FY00 National Defense Authorization Act established this committee under the Federal Advisory Committee Act. Subsequently, the FY04 National Defense Authorization Act removed all non-government employees from the committee, hence eliminating it as a FACA Committee.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*NoAction Reorganize Priorities*No
Outcome Trust In GovernmentNoAction Reallocate ResourcesNo
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchNoAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherNo
Outcome Increased Customer SatisfactionNoAction CommentNA
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherYesNumber Of Grants Reviewed0
Outcome CommentCommittee was removed from FACA status prior to ever having a meeting.Number Of Grants Recommended0
Cost Savings*NoDollar Value Of Grants Recommended$0.00
Cost Savings CommentNAGrants Review CommentNA
Number Of Recommendations*0Access Contact Designated Fed. Officer*No
Number Of Recommendations CommentNAAccess Agency WebsiteNo
% of Recs Fully Implemented*0.00%Access Committee WebsiteNo
% of Recs Fully Implemented CommentNAAccess GSA FACA WebsiteNo
% of Recs Partially Implemented*0.00%Access PublicationsNo
% of Recs Partially Implemented CommentNAAccess OtherYes
Agency Feedback*NoAccess CommentThere is no Committee documentation since the Committee never met. The DFO can answer any questions regarding this issue
Agency Feedback Comment*NANarrative Description*The DoD Pharmacy and Therapeutics Committee was establsihed in the National Defense Authorization Act of FY2000 to make formulary recommendations to the Assistant Secretary of Defense. As of Nov 2004, the Committee has never met and was subsequently terminated in the Natioanl Defense Authorization Act of FY2005.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$0.00Est Payments to Non-Fed Members Next FY*$0.00
Payments to Federal Members*$0.00Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$0.00Estimated Payments to Federal Staff*$0.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$0.00Est Travel Reimb Non-Fed Members nextFY*$0.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$0.00
Other Costs$0.00Est. Other Costs Next FY*$0.00
Total Costs$0.00Est. Total Next FY*$0.00
Federal Staff Support (FTE)*0.00Est. Fed Staff Support Next FY*0.00
Cost RemarksEst Cost Remarks
Hide Section - Interest Areas

Interest Areas

No interest areas selected for this committee.
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-015504Department of Defense Pharmacy and Therapeutics Committee2003
 COM-016956Department of Defense Pharmacy and Therapeutics Committee2002
 COM-017409Department of Defense Pharmacy and Therapeutics Committee2001
 COM-018894Department of Defense Pharmacy and Therapeutics Committee2000